Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;19(6):e70054.
doi: 10.1111/crj.70054.

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System

Hang Chen  1 , Yiming Shen  2 , Yinyu Mu  3 , Shuguang Xu  4 , Shimo Shen  4 , Weiyu Shen  1 , Zeyang Hu  5 , Hongxiang Li  5 , Keyue Qiu  5 , Jiaheng Zhang  5 , Zhe Chen  1 , Guodong Xu  1
Affiliations

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System

Hang Chen et al. Clin Respir J. 2025 Jun.

Abstract

Backgrounds: Pulmonary embolism (PE) is a common disease and a common cause of death. However, it is currently unclear which clinically common drugs can lead to PE.

Methods: We collected, organized, and analyzed reports from the first quarter of 2018 to the fourth quarter of 2022. We performed disproportionality analysis algorithms to calculate reporting odds ratio (ROR), which could quantify the signal values of different adverse events (AEs).

Results: We have screened a total of 3091 drugs, with AE containing "PE" and calculated the ROR signal values of the top 30 drugs reported and ranked them. TESTIM (ROR = 32.03[28.77-35.66]), BARICITINIB (ROR = 23.48[20.55-26.83]), and NUVARIANG (ROR = 19.89[17.13-23.10]) are the drugs with the strongest correlation with PE. In addition, among the 30 drugs with the strongest correlation with PE, most of which are Biologics & Immunomodulators. Therefore, when using these 30 drugs, it is necessary to be alert to the possible risk of PE.

Conclusion: In our study, we filtered 30 common drugs that could cause PE through the FAERS public database, which provides theoretical support for drug selection in the treatment of malignant tumors and IMID.

Keywords: FDA adverse event reporting system; adverse events; drugs; molecular targeted agents; pulmonary embolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
The drug categories of the 30 drugs that most commonly cause pulmonary embolism in the FAERS database.
See this image and copyright information in PMC

References

    1. Mensah G., Wei G., Sorlie P., et al., “Decline in Cardiovascular Mortality,” Circulation Research 120, no. 2 (2017): 366–380. - PMC - PubMed
    1. Sidney S., Quesenberry C., Jaffe M., et al., “Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals,” JAMA Cardiology 1, no. 5 (2016): 594–599. - PubMed
    1. Lubetsky A., “Pulmonary Embolism in Cancer Patients: A Review,” Israel Medical Association Journal: IMAJ 24, no. 3 (2022): 179–182. - PubMed
    1. Mabrouk B., Anis C., Hassen D., et al., “Pulmonary Thromboembolism: Incidence, Physiopathology, Diagnosis and Treatment,” La Tunisie Médicale 92, no. 7 (2014): 435–447. - PubMed
    1. Goldhaber S. and Bounameaux H. J. L., “Pulmonary Embolism and Deep Vein Thrombosis,” Lancet 379, no. 9828 (2012): 1835–1846. - PubMed

MeSH terms